We’ve recently updated our valuation analysis.

Soleno Therapeutics Valuation

Is SLNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLNO?

Other financial metrics that can be useful for relative valuation.

SLNO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does SLNO's PB Ratio compare to its peers?

SLNO PB Ratio vs Peers
The above table shows the PB ratio for SLNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1x
CYTH Cyclo Therapeutics
1.5x27.1%US$14.4m
NEXI NexImmune
0.3x-10.9%US$15.1m
SBFM Sunshine Biopharma
0.4xn/aUS$15.2m
SILO.D Silo Pharma
1.8xn/aUS$14.2m
SLNO Soleno Therapeutics
0.7x66.8%US$14.7m

Price-To-Book vs Peers: SLNO is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1x).


Price to Earnings Ratio vs Industry

How does SLNO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: SLNO is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is SLNO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLNO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SLNO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SLNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SLNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLNO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies